CN101495513B - 促血管生成素-2特异性结合剂 - Google Patents

促血管生成素-2特异性结合剂 Download PDF

Info

Publication number
CN101495513B
CN101495513B CN200580043569.5A CN200580043569A CN101495513B CN 101495513 B CN101495513 B CN 101495513B CN 200580043569 A CN200580043569 A CN 200580043569A CN 101495513 B CN101495513 B CN 101495513B
Authority
CN
China
Prior art keywords
seq
antibody
ang
specific binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580043569.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101495513A (zh
Inventor
J·D·奥利纳
K·格雷汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN101495513A publication Critical patent/CN101495513A/zh
Application granted granted Critical
Publication of CN101495513B publication Critical patent/CN101495513B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200580043569.5A 2004-10-19 2005-10-19 促血管生成素-2特异性结合剂 Expired - Fee Related CN101495513B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US60/620,161 2004-10-19
US10/982,440 2004-11-04
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
CN101495513A CN101495513A (zh) 2009-07-29
CN101495513B true CN101495513B (zh) 2014-08-06

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580043569.5A Expired - Fee Related CN101495513B (zh) 2004-10-19 2005-10-19 促血管生成素-2特异性结合剂

Country Status (10)

Country Link
JP (2) JP2008520188A (https=)
CN (1) CN101495513B (https=)
BR (1) BRPI0518209A (https=)
EA (1) EA011866B1 (https=)
IL (1) IL182279A0 (https=)
MA (1) MA29015B1 (https=)
MX (1) MX2007004247A (https=)
RU (2) RU2404992C2 (https=)
SG (1) SG156668A1 (https=)
ZA (1) ZA200704020B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
HUE034044T2 (en) * 2011-09-30 2018-01-29 Dana Farber Cancer Inst Inc Therapeutic peptides
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
NZ714049A (en) * 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241380T1 (de) * 1999-03-26 2003-06-15 Regeneron Pharma Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU784231B2 (en) * 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ATE536868T1 (de) * 2001-10-12 2011-12-15 Monosolrx Llc Einheitliche filme als schnell auflösende verabreichungsformen enthaltend geschmacksmaskiereden stoff
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
MX2007004247A (es) 2007-06-12
EA011866B1 (ru) 2009-06-30
JP2011207882A (ja) 2011-10-20
CN101495513A (zh) 2009-07-29
ZA200704020B (en) 2008-06-25
SG156668A1 (en) 2009-11-26
IL182279A0 (en) 2007-07-24
MA29015B1 (fr) 2007-11-01
RU2010132956A (ru) 2012-02-10
RU2007118670A (ru) 2008-12-27
EA200700876A1 (ru) 2007-10-26
JP2008520188A (ja) 2008-06-19
BRPI0518209A (pt) 2008-11-04
RU2404992C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
US7658924B2 (en) Angiopoietin-2 specific binding agents
CN101495513B (zh) 促血管生成素-2特异性结合剂
CA2522248C (en) Methods of treatment using specific binding agents of human angiopoietin-2
US7449555B2 (en) Antibodies of angiogenesis inhibiting domains CD148
CN114716544A (zh) 补体组分c5抗体
US8119128B2 (en) Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
WO2007095583A2 (en) Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin
HK1136836A (en) Angiopoietin-2 specific binding agents
ZA200608757B (en) Antibodies of angiogenesis inhibiting domains of CD148
HK1103094A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
HK1103092A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136836

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140806

Termination date: 20141019

EXPY Termination of patent right or utility model
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136836

Country of ref document: HK